20,220 Shares in G1 Therapeutics, Inc. (NASDAQ:GTHX) Purchased by Marathon Trading Investment Management LLC

Marathon Trading Investment Management LLC bought a new stake in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,220 shares of the company’s stock, valued at approximately $46,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Financial Advocates Investment Management acquired a new position in G1 Therapeutics in the 4th quarter valued at $39,000. Los Angeles Capital Management LLC acquired a new stake in shares of G1 Therapeutics in the second quarter valued at about $48,000. SG Americas Securities LLC purchased a new position in shares of G1 Therapeutics in the first quarter worth about $58,000. Capstone Investment Advisors LLC acquired a new position in G1 Therapeutics during the fourth quarter worth about $76,000. Finally, Jump Financial LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at about $105,000. Hedge funds and other institutional investors own 24.21% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. HC Wainwright cut G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of G1 Therapeutics in a report on Wednesday, August 7th. Finally, Wedbush lowered G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th.

G1 Therapeutics Price Performance

GTHX stock opened at $7.15 on Thursday. The firm has a market cap of $373.81 million, a PE ratio of -11.53 and a beta of 1.66. G1 Therapeutics, Inc. has a one year low of $1.08 and a one year high of $7.19. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.12 and a current ratio of 2.48. The firm’s 50 day moving average price is $5.84 and its 200-day moving average price is $4.43.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $16.55 million during the quarter, compared to analysts’ expectations of $15.88 million. G1 Therapeutics had a negative return on equity of 136.98% and a negative net margin of 76.93%. On average, equities research analysts anticipate that G1 Therapeutics, Inc. will post -0.45 EPS for the current year.

G1 Therapeutics Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.